

Afshin Dowlati

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9353017/afshin-dowlati-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

102
papers

9,998
citations

30
h-index

99
g-index

108
ext. papers

12,313
ext. citations

6.8
avg, IF

5.6
L-index

#	Paper	IF	Citations
102	Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2006 , 355, 2542-50	59.2	4760
101	Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , 2018 , 378, 731-739	59.2	1285
100	Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 1929-1939	40	582
99	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. <i>Nature Reviews Cancer</i> , 2019 , 19, 289-297	31.3	304
98	A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. <i>Cancer Research</i> , 2002 , 62, 3408-16	10.1	281
97	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology, The</i> , 2020 , 21, 531-540	21.7	279
96	Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. <i>Cancer Cell</i> , 2017 , 31, 286-299	24.3	240
95	Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. <i>Clinical Cancer Research</i> , 2008 , 14, 1407-12	12.9	225
94	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2386-2394	2.2	162
93	A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. <i>Thyroid</i> , 2009 , 19, 233-40	6.2	150
92	Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. <i>Clinical Cancer Research</i> , 2019 , 25, 6958-6966	12.9	122
91	Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6006-11	2.2	117
90	Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 51-65	21.7	101
89	A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. <i>Clinical Cancer Research</i> , 2009 , 15, 3583-90	12.9	84
88	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. <i>JAMA Oncology</i> , 2019 , 5, 351-357	13.4	84
87	Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. <i>Oncotarget</i> , 2017 , 8, 73745-73756	3.3	65
86	Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance). <i>Journal of Thoracic Oncology</i> , 2017 , 12, 704-713	8.9	49

85	Clinical correlation of extensive-stage small-cell lung cancer genomics. <i>Annals of Oncology</i> , 2016 , 27, 642-7	10.3	48
84	Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. <i>Lung Cancer</i> , 2007 , 55, 349-55	5.9	47
83	Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 459-63	6.1	46
82	Combined SCLC clinical and pathologic characteristics. <i>Clinical Lung Cancer</i> , 2013 , 14, 113-9	4.9	43
81	Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. <i>Clinical Cancer Research</i> , 2005 , 11, 7938-44	12.9	43
80	Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, 1 st line small cell lung cancer: Results from the phase 2 TRINITY study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8507-8507	2.2	40
79	Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019 , 37, 87-97	4.3	39
78	RET mutation and expression in small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1316-23	8.9	37
77	RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR. <i>Oncotarget</i> , 2017 , 8, 5992-6002	3.3	35
76	Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival. <i>Clinical Cancer Research</i> , 2014 , 20, 5124-32	12.9	32
75	The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent. <i>Molecular Cancer Research</i> , 2009 , 7, 1854-60	6.6	32
74	Protein inhibitor of activated STAT3 expression in lung cancer. <i>Molecular Oncology</i> , 2011 , 5, 256-64	7.9	30
73	Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2309-18	2.2	30
72	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , 2019 , 25, 210-221	12.9	30
71	Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. <i>Lung Cancer</i> , 2007 , 56, 377-81	5.9	28
70	Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 47, 141-8	3.5	26
69	Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer. <i>Cancer Medicine</i> , 2019 , 8, 1459-1466	4.8	24
68	Multi-institutional phase I trials of anticancer agents. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1926-31	2.2	23

67	A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. <i>British Journal of Cancer</i> , 2021 , 124, 744-753	8.7	23
66	Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. <i>International Journal of Cancer</i> , 2009 , 125, 1728-34	7.5	22
65	A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. <i>Oncologist</i> , 2016 , 21, 1163-1164	5.7	22
64	Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma. <i>Journal of Clinical Pathology</i> , 2018 , 71, 1108-1115	3.9	21
63	KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, e489-e501	4.9	20
62	Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2015 , 20, 1298-303	5.7	18
61	PIAS3 expression in squamous cell lung cancer is low and predicts overall survival. <i>Cancer Medicine</i> , 2015 , 4, 325-32	4.8	18
60	CD30 is a potential therapeutic target in malignant mesothelioma. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 740-6	6.1	16
59	Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution. <i>Clinical Lung Cancer</i> , 2014 , 15, 207-12	4.9	15
58	Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer. <i>Future Oncology</i> , 2017 , 13, 1405-1414	3.6	15
57	A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors. <i>Investigational New Drugs</i> , 2011 , 29, 126-30	4.3	15
56	Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer. <i>PLoS ONE</i> , 2014 , 9, e106784	6.7	14
55	A detailed smoking history and determination of status predict response to checkpoint inhibitors in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020 , 9, 55-60	4.4	13
54	SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2. <i>Anti-Cancer Drugs</i> , 2008 , 19, 9-16	2.4	13
53	Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 65, 73-8	3.5	12
52	Phase II study of olatumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. <i>Lung Cancer</i> , 2017 , 111, 108-115	5.9	11
51	PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. <i>International Journal of Cancer</i> , 2014 , 134, 1045-54	7.5	11
50	Hunting and trapping the vascular endothelial growth factor. <i>Journal of Clinical Oncology</i> , 2010 , 28, 185-7.2	7.2	11

49	Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. <i>Molecular Oncology</i> , 2018 , 12, 2124-2135	7.9	10
48	A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. <i>Investigational New Drugs</i> , 2019 , 37, 738-747	4.3	9
47	Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer. <i>Investigational New Drugs</i> , 2018 , 36, 435-441	4.3	9
46	Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine. <i>Radiotherapy and Oncology</i> , 2016 , 121, 335-341	5.3	9
45	Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , 147-62	7.1	9
44	Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 547-53	3.5	9
43	Relationship between phase I study duration and symptom burden. <i>Supportive Care in Cancer</i> , 2018 , 26, 731-737	3.9	8
42	Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2005 , 23, 563-7	4.3	8
41	Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. <i>Cancer Medicine</i> , 2021 , 10, 3862-3872	4.8	8
40	A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 4574-84	12.9	8
39	Identification of STAT3-independent regulatory effects for protein inhibitor of activated STAT3 by binding to novel transcription factors. <i>Cancer Biology and Therapy</i> , 2011 , 12, 139-51	4.6	7
38	Oral combination chemotherapy in the management of AIDS-related lymphoproliferative malignancies. <i>Drugs</i> , 1999 , 58 Suppl 3, 99-107	12.1	7
37	Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data. <i>Practical Radiation Oncology</i> , 2016 , 6, e163-e169	2.8	7
36	Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 744724	5.3	6
35	Identification of RUNX1T1 as a potential epigenetic modifier in small-cell lung cancer. <i>Molecular Oncology</i> , 2021 , 15, 195-209	7.9	6
34	Phase I Clinical Trials in Patients 80. <i>Journal of Geriatric Oncology</i> , 2011 , 2, 142-146	3.6	5
33	Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy. <i>Seminars in Cancer Biology</i> , 2021 ,	12.7	5
32	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. <i>British Journal of Cancer</i> , 2021 ,	8.7	5

31	Role of mTOR As an Essential Kinase in SCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1522-1534	8.9	4
30	LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. <i>Investigational New Drugs</i> , 2021 , 39, 1057-1071	4.3	4
29	Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. <i>JAMA Dermatology</i> , 2017 , 153, 413-420	5.1	3
28	Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 166-166	2.2	3
27	Genomic alterations in small cell lung cancer and their clinical relevance. <i>Translational Lung Cancer Research</i> , 2016 , 5, 450-1	4.4	3
26	Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2021 , 39, 142-151	4.3	3
25	Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer. <i>Clinical Lung Cancer</i> , 2008 , 9 Suppl 2, S71-5	4.9	2
24	Phase I Trial of the Base Excision Repair Blocker Methoxyamine (TRC-102) Combined with Fludarabine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies. <i>Blood</i> , 2014 , 124, 4688-4688	2.2	2
23	First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3063-3063	2.2	2
22	Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS9080-TPS9080	2.2	2
21	Imaging features of gastrointestinal toxicity in non-small cell lung cancer patients treated with erlotinib: A single institute 13-year experience. <i>Clinical Imaging</i> , 2020 , 68, 210-217	2.7	2
20	A randomized controlled trial of structured palliative care versus standard supportive care for patients enrolled in phase 1 clinical trials. <i>Cancer Medicine</i> , 2021 , 10, 4312-4321	4.8	2
19	A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021 , 124, 391-398	8.7	2
18	Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival. <i>Clinical Lung Cancer</i> , 2021 , 22, 16-22.e1	4.9	2
17	Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy. <i>Practical Radiation Oncology</i> , 2019 , 9, e129-e133	2.8	1
16	Combination chemotherapy with topotecan for non-small cell lung cancer. <i>Lung Cancer</i> , 2003 , 41 Suppl 4, S23-6	5.9	1
15	Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21680-e21680	2.2	1
14	Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer. <i>Reviews on Recent Clinical Trials</i> , 2017 , 12, 51-58	1.2	1

13	Combination of quantitative features from H&E biopsies and CT scans predicts response to chemotherapy and overall survival in small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8572-8572	2.2	1
12	Role of radiation in extensive stage small cell lung cancer: a National Cancer Database registry analysis. <i>Future Oncology</i> , 2021 , 17, 2713-2724	3.6	1
11	Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.. <i>Lung Cancer</i> , 2022 , 166, 135-142	5.9	1
10	Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions. <i>Journal of Neuroendocrinology</i> , 2021 , 33, e12943	3.8	0
9	Trends in imaging utilization for small cell lung cancer: a decision tree analysis of the NCCN guidelines. <i>Clinical Imaging</i> , 2021 , 75, 83-89	2.7	0
8	Genomic analyses of high-grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities. <i>Molecular Oncology</i> , 2021 , 15, 3545-3558	7.9	0
7	Temporal evolution of patient characteristics enrolled on phase I trials. <i>Investigational New Drugs</i> , 2011 , 29, 312-5	4.3	
6	Stereotactic body radiotherapy (SBRT) for T2N0 (>3 cm) non-small cell lung cancer: Outcomes and failure patterns. <i>Journal of Radiosurgery and SBRT</i> , 2021 , 7, 271-277	0.4	
5	RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS9081-TPS9081	2.2	
4	Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer. <i>Clinical and Translational Science</i> , 2021 , 14, 664-670	4.9	
3	Final report of an open-label phase II trial of bevacizumab plus docetaxel and gemcitabine in metastatic, previously untreated nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e18046-e18046	2.2	
2	Clinical trial design in small cell lung cancer: Surrogate endpoints and statistical evolution.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7087-7087	2.2	
1	Phase I expansion study of sunitinib and bevacizumab in patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e13521-e13521	2.2	